Study finds semaglutide preserves lean body mass better than tirzepatide
Updated
Updated · Healthline · Apr 27
Study finds semaglutide preserves lean body mass better than tirzepatide
14 articles · Updated · Healthline · Apr 27
In a medRxiv preprint of 7,965 new GLP-1 users, tirzepatide was linked to 1.1% more lean mass loss at three months and 2% more at 12 months.
Researchers said tirzepatide’s greater overall weight loss may partly explain the trade-off, with about 10% of users seeing 20% weight loss and 5% lean mass loss, versus 7% on semaglutide.
The findings add caution to booming obesity-drug use, highlighting muscle-loss risks and the importance of strength training, protein intake, dose titration and monitoring, though the study has not yet been peer-reviewed.
Are popular weight-loss drugs creating a hidden health crisis by prioritizing pounds lost over muscle preserved?
Genetics can now predict a drug's side effects. Is your DNA the key to safer, more effective weight loss?